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Abstract
Introduction: Sandfly fever virus (SFV) serotypes sandfly fever Naples virus, sandfly fever Sicilian virus, and
sandfly fever Cyprus virus cause febrile diseases, whereas Toscana virus (TOSV) is responsible for aseptic
meningoencephalitis. Diagnosis and surveillance of TOSV depend heavily on virus serology, and various
commercial assays utilizing various antigen sources and formats have been available. The aim of this study
was to perform comparative evaluation of commercially available serological assays for anti-TOSV immuno-
globulins.
Materials and Methods: A collection of 120 sera from healthy blood donors from an endemic region, previously
identified to be reactive for antibodies against various SFV serotypes by indirect immunofluorescence test (IIFT),
was reevaluated for IgG/IgM via IIFT, enzyme-linked immunosorbent assay, and an immunoblot assay man-
ufactured by Euroimmun, Diesse, and Mikrogen, respectively. Virus neutralization test (VNT) was performed
for 99 sera using standard TOSV, sandfly fever Sicilian virus, and sandfly fever Naples virus strains.
Results: A total of 89 samples (74.2%) were reactive for TOSV IgG in at least one of the commercial assays, and
31 samples (31.3%) were reactive in VNT for various SFV serotypes. Average percentage agreements among
commercial assays and between VNT and the commercial assays were noted as 57.8% and 62.6%, respectively.
No significant correlation between assay results and VNT titers was observed. SFV IgM antibodies were de-
tected in a total of eight samples (6.7%) via IIFT, which were nonreactive in enzyme-linked immunosorbent
assay and VNT.
Discussion: Commercial diagnostic immunoassays displayed slight to fair agreement for TOSV IgG as assessed
via kappa and percentage agreement values. The results could only be confirmed via virus neutralization in a
portion of the samples, and overall agreement between the commercial assays and VNT was slight. Commercial
assays such as immunoblot can be used in addition to VNT for confirmation of TOSV exposure.
Key Words: Diagnosis—Sandfly fever virus—Serology—SFV—Toscana virus—TOSV.
Introduction
Sandfly fever vıruses (SFVs; family Bunyaviridae, genusPhlebovirus) are arthropod-borne viruses transmitted to
humans by the bite of phlebotomine sandflies (Mertz 1997).
Certain SFV serotypes, namely, sandfly fever Sicilian virus
(SFSV), sandfly fever Naples virus (SFNV), and sandfly fever
Cyprus virus (SFCV), are responsible for a self-limited febrile
condition, whereas Toscana virus (TOSV) displays a distinct
neurotropism and may cause aseptic meningoencephalitis in
the infected individuals (Dionisio et al. 2003). In endemic re-
gions, such as countries in the Mediterranean basin, exposure
to SFVs is common as revealed by serosurveys, and TOSV
infections account for a high proportion of human aseptic
meningitis (Eitrem et al. 1991a, Nicoletti et al. 1996,
Hemmersbach-Miller et al. 2004, Sanbonmatsu-Gamezet al. 2005).
In acute cases, methods for the diagnosis of TOSV infec-
tions include direct detection of the virus in patient samples
either by culture or by nucleic acid amplification techniques
and virus serology (Dionisio et al. 2003, Hemmersbach-Miller
1Department of Medical Microbiology, Virology Unit, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
2Center for Biological Security (ZBS-1), Robert Koch Institute, Berlin, Germany.
3Institute of Virology, University Medical Center, Go¨ttingen, Germany.
4Middle Anatolia Regional Blood Center, Turkish Red Crescent Society, Ankara, Turkey.
VECTOR-BORNE AND ZOONOTIC DISEASES
Volume 11, Number 6, 2011
ª Mary Ann Liebert, Inc.
DOI: 10.1089/vbz.2010.0224
781
et al. 2004, Sanbonmatsu-Gamez et al. 2005). Investigation of
TOSV-specific immunoglobulins is also important for identi-
fying virus exposure in healthy subjects from endemic coun-
tries or in regions where the sandfly vectors are present
(Dionisio et al. 2003). The early phase of the SFV disease is
characterized by a slow increase in specific IgMs, followed by
IgG several days afterward in the serum (Echevarria et al.
2003). IgM can still be detected at least 1 year after the expo-
sure, whereas IgG levels slowly increase, reaching a peak
in the convalescent phase and persists for several years
(Magurano and Nicoletti 1999). Various methods can be used
for the detection of TOSV IgM and/or IgG antibodies, in-
cluding hemagglutination inhibition, indirect immunofluo-
rescence test (IIFT), enzyme-linked immunosorbent assay
(ELISA), immunoblot (IB), and virus neutralization test (VNT)
(Clarke and Cassals 1958, Eitrem et al. 1991b, Schwarz et al.
1995, 1996, Magurano and Nicoletti 1999). Some of these as-
says are commercially available and have been developed
with partially purified antigens, infected cells, or recombinant
viral proteins (Eitrem et al. 1991b, Schwarz et al. 1995,
Schwartz et al. 1998, Ciufolini et al. 1999).
Exposure to a particular SFV serotype does not protect
from infection with another serotype, and cross-reactions in
serological tests can be frequently observed (Dionisio et al.
2003). Pre-existing antibodies against SFV serotypes other
than TOSV (SFSV or SFNV) may also interfere with the TOSV
serology results and can be interpreted as false-positive due to
the cross-reactivity. This is more likely to occur when partially
purified virus extracts or SFV-infected cells are employed as
the source of antigens in the assay used for the diagnosis or
surveillance (Schwarz et al. 1995, Magurano and Nicoletti
1999). During human immune response to TOSV infection, N
protein has been identified as the immunodominant antigen,
which has later been used for developing diagnostic assays
with recombinant proteins (Ciufolini et al. 1999, Cusi et al.
2001). The recombinant N protein-based assays have been
previously evaluated and have performed well, especially for
acute TOSV infections (Valassina et al. 1998, Soldateschi et al.
1999). Nevertheless, cross-reactivity in phlebovirus serology
affects the assays that employ TOSV N protein as well, es-
pecially in regions where different phleboviruses co-circulate,
due to the presence of highly conserved regions in the viral
nucleocapsid (Magurano and Nicoletti 1999, Di Bonito et al.
2002). To discriminate among related phleboviruses, it is re-
commended to complement recombinant N-protein-based
serodiagnosis with VNT (Calisher et al. 1999, Dionisio et al.
2003). However, phlebovirus neutralization has been shown
to be mediated only partially by antibodies to the nucleo-
capsid, and immunity to viral envelope glycoproteins also
plays a role (Cusi et al. 2001, Di Bonito et al. 2002). The im-
mune response to viral glycoproteins has been shown to differ
among patients, whereas all exposed persons develop anti-
bodies against linear epitopes of N protein (Di Bonito et al.
2002). Interpretation of serological assay results in endemic
regions may be more difficult, due to frequent recent infec-
tions and/or reinfections that boost immunity (Calisher et al.
1999, Dionisio et al. 2003).
The aim of this study was to evaluate the performances of
all commercially available serological assays utilizing various
antigen sources for detecting anti-TOSV antibodies, com-
pared to virus neutralization in samples from a TOSV and
SFV endemic region (Ergu¨nay et al. 2010).
Materials and Methods
Samples and commercial assays
Serum samples reactive for SFV IgG by a commercial IIFT
(SFV IgG mosaic I; Euroimmun) performed during a sero-
surveillance study in Central Anatolia, Turkey, were em-
ployed in the study (Ergu¨nay et al. 2010). The samples
originated from healthy blood donors andwere obtained after
informed consent. The IIFT allows simultaneous detection of
antibodies against four viral serotypes (SFSV, SFNV, TOSV,
and SFCV) and was performed as indicated by the manu-
facturer. A total of 120 samples were retested via this assay
before inclusion in the study and reactive sera were divided
into six panels according to the IIFT IgG reactivity against
different viral serotypes: Panel 1: SFSV (n:18); Panel 2: SFNV
(n:11); Panel 3: TOSV (n:46); Panel 4: SFCV (n:7); Panel 5:
SFSVþSFCV (n:13); and Panel 6: SFNVþTOSV (n:25). All
samples were further evaluated for SFV IgM by a commercial
IIFT (SFV IgM Mosaic I; Euroimmun), for TOSV IgM/IgG by
a commercial ELISA (TOSV IgG and IgM; Diesse) and by a
commercial IB assay for TOSV IgG (recomLine Bunyavirus
IgG/IgM; Mikrogen) according to the manufacturers’ in-
structions. In addition to TOSV, antibodies to certain Hanta-
virus serotypes (Hantaan, Puumala, Dobrava, and Seoul) can
also be simultaneously detected via the IB. In the IIFT, anti-
body levels were determined starting at the serum dilution of
1:100. The positive results were evaluated as equivocal
(1/100), positive (1/320), or strong positive (1/1000 or higher)
according to visual intensity of fluorescence compared to
control sera. In the ELISA, qualitative evaluation of the results
was performed by comparing the average optic density of the
sample with the cutoff control. When the sample to cutoff
ratio was >1.2, the sample was interpreted as positive and
borderline if the ratio was between 1.2 and 0.8. The IB results
are interpreted according to the visual intensity of the cutoff
control where intensities equal to the cutoff as positive (þ) and
stronger than the cutoff as strong positive (þþ, þþþ) as in-
dicated by the manufacturer. The general features and per-
formance characteristics of the commercial assays are
provided in Table 1.
Virus neutralization test
VNT for SFVs were performed in 96-well microtiter plates
with Vero cells (ATCC CCL81) and was adapted from the
VNT used for Rift Valley fever virus described previously
(Davies et al. 1988). Serial serum dilutions of 1/10 to 1/320
and virus suspensions of 108 TCID50 were prepared with
standard strains (SFSV Oct-85 Sabin, SFNV Oct-85 Sabin and
TOSV ISS.Phl.3). The viruses were then diluted to contain a
final concentration of 100 TCID50 per 50mL. The diluted virus
and serum dilutions were distributed into all wells excepted
for the controls. After an hour of incubation at 378C, Vero cells
(*2.105 in number per well) in 10% fetal calf serum were
added to the serum–virus complex. Cells were evaluated after
72 and 96 h of incubation at 378C, and reactivity was deter-
mined by the lack of cytopathogenic effect above a serum
dilution of 1/20 at the 96th hour.
Statistical analysis
Agreement among commercial assays by the Kappa, Fleiss’
Kappa coefficients (Landis and Koch 1977, Ilstrup 1990), and
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comparison of antibody titers were performed by SPSS
package version 17.0 (SPSS Inc.).
Results
Detection of SFV/TOSV IgG and IgM seroreactivity
by commercial assays
The distribution of positive/equivocal/tested results and
antibody titers for SFV serotypes according to the IIFT sub-
strate are given in Table 2. Overall rate of equivocal/positive
results from TOSV IIFT and ELISA were 18/53 (total: 71/120;
59.2%) and 10/8 (total:18/120; 15%), respectively. Positive/
strong positive results from TOSV IgG IBwere 9/43 (total:52/
120; 43.3%) (Table 2). No reactivity for Hantavirus serotypes
was observed in any of the IB reactive samples.
For SFV IgM, a total of eight samples (8/120, 6.7%) were
reactive (positive or equivocal) in the IIFT (Table 2). The dis-
tribution of SFV serotypes identified was SFNV in 3, SFSV in
2, TOSV in 1, and SFSVþSFCV in 1 sample. IgM IIFT titers
observed are given in Table 2. All samples were negative with
the TOSV IgM ELISA, and one SFNV IgM IIFT reactive
sample was positive in TOSV IgG ELISA. IB assay for TOSV
IgM was not performed.
VNT results
VNTs for SFSV, SFNV, and TOSV were performed for 99
samples, excluding 21 due to insufficient amounts. A total of
31 samples (31/99; 31.3%) were reactive in the VNTs that
comprise 15 TOSV (15.2%), 11 SFSV (11.1%), and 3 SFNV
(3.03%) (Table 3). Two samples were observed to possess
neutralizing antibodies for more than one SFV serotype and
displayed reactivity for SFSV and SFNV where the titer of
SFSV (1/320) exceeded that of SFNV (1/40 and 1/80) (Table
3). None of the IgM-positive samples were reactive in VNTs,
and for the sample with SFSVþSFCV IgM positivity, VNT
was not performed. The presence of neutralizing antibodies
for TOSV could be demonstrated in 15 of the 89 samples
(16.9%) reactive in any of the commercial assays and in 15 of
60 samples (25%) reactive with TOSV IIFT. In samples with
IIFT reactivity other than TOSV, 41.9% (13/31) and 9.7%
(3/31) were positive in VNTs for SFSV and SFNV, respec-
tively (Table 3).
Evaluation of TOSV commercial assays
A total of 31 samples (31/120; 25.8%) were observed as
negative for TOSV IgG and 89 samples (89/120; 74.2%) were
reactive in at least one of the commercial assays (positive and
equivocal results interpreted as reactive). Thirteen samples
(13/89; 14.6%) were reactive in all assays. Reactivity in
IIFTþIB and IIFTþELISA only were noted in 25 (28.1%) and 2
(2.2%) samples, respectively. For equivocal samples in IIFT, 12
out of 18 were observed as negative in ELISA or IB. In 49
samples (49/89; 55.1%), reactivity was observed via a single
assay (31 in IIFT, 14 in IB, and 4 for ELISA). No significant
correlation among IIFT titers, ELISA optical densities, and/or
VNT titers could be demonstrated (data not shown).
Agreement among commercial assays, assessed via kappa
coefficient, was observed as slight to fair, and percentage
agreement values were calculated as 50%–63% (average:
57.8%) (Table 4). When results from all commercial assays
(IIFTþELISAþIB)were evaluated via Fleiss kappa, the overall
agreement was noted as slight (K: 0.116). The agreement be-
tween VNT and the commercial assays was slight to fair, with
percentage agreement values between 53% and 82% (average:
62.6%) (Table 4). Fleiss kappa for VNT and the commercial
assays also displayed slight agreement (K: 0.151).
Discussion
TOSV is one of the major viral pathogens involved in
aseptic meningoencephalitis occurring during summer in
Mediterranean countries and poses a threat to the residents as
well as the travelers (Eitrem et al. 1991b, Charel et al. 2005).
Due to the frequent co-circulation of various SFV serotypes
that cross-react in serological assays, the detection of im-
mune responses to TOSV can be challenging (Magurano and
Nicoletti 1999, Dionisio et al. 2003). Although a number of
commercial assays have been developed for the serological
detection of TOSV exposure, data on the performances of
these assays have not been available. In this study, we eval-
uated the most widely used commercial assays for detecting
Table 1. General Characteristics of the Commercial Assays Evaluated in the Study
IIFT ELISA IB
Manufacturer Euroimmun Labordiagnostika AG Diesse Diagnostica Mikrogen Diagnostik
Assay format Immunofluorescent assay Enzyme immunoassay Strip immunoassay
Antigen source Cell culture grown viruses Recombinant N protein Recombinant N protein
Target TOSV IgM/IgG SFSV, SFNV,
SFCV IgM/IgG
TOSV IgM/IgG TOSV IgM/IgG Hantavirus
IgM/IgG
Sample Serum/plasma Serum/plasma Serum/plasma
Turnaround time *1 h 15min *1 h 50min *4 h 45min
Hands-on time *15min *15min *45min
Interpretation Fluorescent microscopy Optic density measurement Visual
Sensitivitya Not available 100% (IgM) 100% (IgM)
95.0% (IgG) 100% (IgG)
Specificitya Not available 100% (IgM) 99% (IgM)
96.5% (IgG) 99% (IgG)
aAs provided by the manufacturer.
IIFT, indirect immunofluorescence test; ELISA, enzyme-linked immunosorbent assay; IB, immunoblot; TOSV, Toscana virus; SFSV, Sicilian
virus; SFNV, sandfly fever Naples virus; SFCV, sandfly fever Cyprus virus.
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TOSV immunoglobulins. In addition, a significant number of
the samples (99/120; 82.5%) were investigated for the pres-
ence of neutralizing antibodies to SFSV, SFNV, and TOSV as
well. Since IgM for TOSV and other SFVs were only detected
in a small number of samples in the study group via IIFT/
ELISA (n:8) and VNTs were observed to be negative, we did
not perform the IB assay for IgM reactive samples or com-
pared IgM results. This constitutes the main limitation of this
study. Nevertheless, viral RNAdetection has been established
as a powerful tool and an effective alternative for identifying
acute TOSV infections (Charel et al. 2005). The impact of viral
RNA detection in TOSV-associated central nervous system
infections in the study region has also been documented re-
cently, where TOSV IgM was identified via IIFT in only 4
(25%) of the 16 TOSV RNA positive sera (Ergu¨nay et al. 2010).
For TOSV IgG, the commercial assays evaluated in this
study were observed to display slight to fair agreement with
an average percentage of 57.8%. This relatively low agreement
observed is presumably due to the viral antigens employed,
as well as differences in assay configurations, as displayed
previously (Calisher et al. 1999, Cusi et al. 2001, Di Bonito et al.
2002). While virus-infected cells are the source of the antigens
in the IIFT, recombinant N protein of TOSV is used in the
ELISA and IB, although in different matrices. The TOSV IIFT
Table 3. Assay Results for the Virus Neutralization Test Reactive Samples
IIFT (titer: [1/x]) VNT (titer: [1/x])
Sample no. SFSV SFNV TOSV SFCV ELISA (ratio) IB SFSV SFNV TOSV
1 n 320 n n 0.459 1þ n 160 n
2 n 320 n n 0.391 1þ n 160 n
3 n 320 n n 0.496 2þ n 80 n
4 1000 n n n 1.305 n 320 n n
5 100 n n n 0.245 n 320 n n
6 320 n n n 0.481 1þ 320 n n
7 100 n n n 0.718 1þ 320 80 n
8 320 n n n 0.162 1þ 320 n n
9 320 n n n 0.289 n 320 n n
10 100 n n n 0.093 n 320 n n
11 320 n n n 0.518 n 40 n n
12 320 n n n 0.185 n 80 n n
13 1000 n n n 0.082 n 320 n n
14 n n 1000 n 0.450 2þ n n 40a
15 n n 320 n 0.358 2þ n n 40a
16 n n 1000 n 0.507 2þ n n 40a
17 n n 320 n 0.879 2þ n n 40a
18 n n 1000 n 0.873 2þ n n 40
19 n n 1000 n 0.684 1þ n n 40
20 n n 320 n 0.724 2þ n n 40
21 n n 320 n 0.366 2þ n n 40
22 n n 1000 n 0.784 3þ n n 40
23 n n 1000 n 0.633 2þ n n 40
24 n n 320 n 0.157 n n n 40
25 n >1000 >1000 n 3.661 3þ n n 40
26 n >1000 1000 n 2.951 3þ n n 40
27 n 320 1000 n 2.317 3þ n n 40
28 n 100 320 n 0.898 3þ n n 40
29 >1000 n n >1000 0.670 n 320 n n
30 >1000 n n >1000 0.430 2þ 320 n n
31 1000 n n 1000 0.270 1þ 320 40 n
n, Negative.
Shown in bold are ELISA equivalent/positive results.
aNo further titration.
Table 4. Agreement Among Commercial Assays and Virus Neutralization Test
for Toscana Virus IgG Detection
IIFT (Kappaa/% agreement) ELISA (Kappa/% agreement) IB (Kappa/% agreement) VNT (Kappa/% agreement)
IIFT – 0.111/50 0.235/60.8 0.179/53.3
ELISA 0.111/50 – 0.175/62.5 0.248/81.7
IB 0.235/60.8 0.175/62.5 – 0.278/67.5
aInterpreted <0 as no agreement and 0–0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1 as almost
perfect agreement.
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titers were significantly higher in VNT reactive than nonre-
active samples, with TOSV antibody titers equal to or higher
than 1/320 in all VNT reactive samples. Similar findings were
also noted for the majority of the SFSV/SFNV reactive sam-
ples as well. Thus, the IIFT can be used for screening pur-
poses, but equivocal evaluations might require retesting and/
or confirmation. Amajor advantage of the IIFT is the detection
of the antibody responses against four different SFV sero-
types, enabling identification of probable cross-reactions.
Nevertheless, IIFT is a labor-intensive method that requires
the individual examination of all samples in the fluorescent
microscope, and the interpretation can vary according to the
microscopist.
In TOSV ELISA, equivocal and positive results were
equally distributed in VNT-reactive samples and in samples
reactive via TOSV IIFT or IB (data not shown). Thus, equiv-
ocal results from this assay strongly imply reactivity. The
TOSV IB assay displayed reactivity in all SFNV VNT-positive
samples and in the majority of the SFNV and SFNVþTOSV
IIFT reactive samples, which suggests cross-reactions with
SFNV. However, this assay provided negative results in the
majority of the IIFT or ELISA equivocal samples and positive
results in the majority of the TOSV VNT-positive samples.
Thus, IB can be employed as a confirmatory assay for TOSV
exposure for samples reactive in TOSV IIFT or ELISA. The
ELISA format enables rapid testing and interpretation in a
high number of samples and can be easily automated. It has
been previously reported that for TOSV, the performance of
whole virus and recombinant nucleocapsid ELISAs correlate
well (Valassina et al. 1998). However, the relatively lower
sensitivity observed for the ELISA, as compared to IIFT and
VNT, suggests that the seroprevalence rates might have been
underestimated in the previous studies where this assay was
employed for surveillance (Echevarria et al. 2003, Valassina et
al. 2003, Terrosi et al. 2009). The IB assay requires longer
hands-on time than ELISA or IIFT but provides data about
Hantavirus exposure (serotypes Hantaan, Puumala, Dobrava,
Seoul) in the same strip as well.
An interesting finding is that VNT, which is generally re-
garded as the gold-standard assay for specificity, has pro-
vided confirmation only in a portion of the samples reactive
for TOSV immunoglobulins via any assay and observed to be
relatively insensitive. Moreover, the agreement of VNT and
the commercial assays was interpreted as slight. It has been
known that phleboviral neutralization is a complex phe-
nomenon involving a number antigenic epitopes and even the
majority of the exposed persons develop antibodies against
linear epitopes of N protein, the immune response against
viral glycoproteins, which affects virus neutralization in vitro,
have been shown to display considerable variation (Besselaar
and Blackburn 1991, Di Bonito et al. 2002). Patients with
TOSV-induced neurological disease have also been observed
to develop a differential antibody response against denatured
viral proteins (Di Bonito et al. 2002). The presence of TOSV
glycoprotein-precititating antibodies were associated with
higher neutralizing antibody titers in acute and convelescent
sera (Magurano and Nicoletti 1999). In addition, neutralizing
epitopes may not necessarily be detected in diagnostic assays
andmay depend on tertiary structures thatmay be lost during
assay development (Magurano and Nicoletti 1999, Di Bonito
et al. 2002). These variations may account for the slight
agreement observed among commercial diagnostic assays
and VNT. A similar phenomenon has also been described for
mosquito-borne flavivirusesWest Nile virus and Yellow fever
virus, where correlation of ratio/titers of ELISA or IIFT to
VNT has observed to be low (Niedrig et al. 1999, Niedrig et al.
2007). Nevertheless, VNTs are still essential for ser-
oepidemiological studies for confirming the presence of neu-
tralizing antibodies. It also remains to be verified if surface
glycoprotein variants of TOSV also co-circulate in endemic
areas and are involved in human immune response with
probable consequences in diagnostic serology. Nevertheless,
it is likely that TOSV diagnostic assays will significantly
benefit from inclusion of viral glycoprotein antigens in addi-
tion to nucleocapsid.
In conclusion, commercially available diagnostic immu-
noassays displayed slight-to-fair agreement as determined for
IgG in sera from asymptomatic blood donors from an en-
demic region. The results could only be confirmed via virus
neutralization in a portion of the samples, and overall agree-
ment between the commercial assays and VNT is slight. The
IIFT could be used for screening purposes, and for confir-
mation of TOSV exposure, commercial assays such as IB can
be performed in addition to VNT.
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